Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Baijin Life Science HoldingsMNNGF 26 Earnings Yield (Joel Greenblatt) % is -7.80% as of Mar. 2026. GuruFocus rates MNNGF with a GF Score™ of 26/100 and a GF Value™ of $0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,132 Retail - Cyclical companies, Baijin Life Science Holdings ranks worse than 87.19% on this metric.
Baijin Life Science Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was $68.94 Mil.
Baijin Life Science Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.40 Mil. Baijin Life Science Holdings's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was -7.80%.
The historical rank and industry rank for Baijin Life Science Holdings's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
MNNGF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1015.14 Med: -3.77 Max: 5.34
Current: -4.23
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Baijin Life Science Holdings was 5.34%. The lowest was -1015.14%. And the median was -3.77%.
MNNGF's Earnings Yield (Joel Greenblatt) % is ranked worse than 87.19% of 1132
companies
in the Retail - Cyclical industry
Industry Median: 5.565
vs MNNGF: -4.23
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Baijin Life Science Holdings's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Baijin Life Science Holdings Earnings Yield (Joel Greenblatt) % Related Terms
Baijin Life Science Holdings Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Baijin Life Science Holdings's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baijin Life Science Holdings Earnings Yield (Joel Greenblatt) % Chart
MNNGF vs TPR: Earnings Yield (Joel Greenblatt) % Comparison
For the Luxury Goods subindustry, Baijin Life Science Holdings's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baijin Life Science Holdings Earnings Yield (Joel Greenblatt) % vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Baijin Life Science Holdings's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Baijin Life Science Holdings's Earnings Yield (Joel Greenblatt) % falls into.
Baijin Life Science Holdings Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Baijin Life Science Holdingss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2026 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of -7.80% mean?
Baijin Life Science Holdings (MNNGF) has a Earnings Yield (Joel Greenblatt) % of -7.80% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Baijin Life Science Holdings and its competitors. According to the industry distribution chart, Baijin Life Science Holdings ranks #987 out of 1132 companies in the Retail - Cyclical industry, placing it in the top 87.2%.
Is Baijin Life Science Holdings' Earnings Yield (Joel Greenblatt) % too high?
Baijin Life Science Holdings' current Earnings Yield (Joel Greenblatt) % is -7.80%. Based on the distribution chart, Baijin Life Science Holdings ranks #987 out of 1132 companies in the Retail - Cyclical industry, which is in the bottom quartile relative to peers. Overall, Baijin Life Science Holdings has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Baijin Life Science Holdings' Earnings Yield (Joel Greenblatt) % compare to TPR?
According to the Retail - Cyclical industry distribution chart, Baijin Life Science Holdings ranks #987 out of 1132 companies for Earnings Yield (Joel Greenblatt) %. This places Baijin Life Science Holdings in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 5.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Retail - Cyclical company?
The median Earnings Yield (Joel Greenblatt) % among Retail - Cyclical companies is 5.57, based on 1,132 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Baijin Life Science Holdings and its competitors. For the Retail - Cyclical industry, the median Earnings Yield (Joel Greenblatt) % is 5.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Baijin Life Science Holdings's current Earnings Yield (Joel Greenblatt) % is -7.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baijin Life Science Holdings stock overvalued right now?
Based on GuruFocus' analysis, Baijin Life Science Holdings (MNNGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.08 — trading 60% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -7.80%. Baijin Life Science Holdings' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Baijin Life Science Holdings (MNNGF), the current Earnings Yield (Joel Greenblatt) % is -7.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Baijin Life Science Holdings (MNNGF) Overvalued in 2026?
Based on GuruFocus' analysis, Baijin Life Science Holdings stock appears to be overvalued.
The current stock price of $0.08 is trading 60% above its estimated GF Value™ of $0.05.
GuruFocus considers Baijin Life Science Holdings to be Significantly Overvalued.
Key valuation signals for MNNGF:
Earnings Yield (Joel Greenblatt) %: -7.80%
GF Value™: $0.05 vs. price of $0.08 (60% above fair value)
No single metric tells the full story. See the MNNGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company has three business segment: jewelry business segment; strategic investment segment; and skincare business segment. The majority of revenue is coming from jewelry business segment.
26GF Score
Get the complete analysis for MNNGF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNNGF has been successfully added to your 
